Quoin Pharmaceuticals: Leveraging the Value Proposition of Partnerships
Stock up 6% on better-than-average volume on news of company’s fifth distribution partnership and analyst coverage update
Advancing global support for rare disease treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) is harnessing the power of partnerships to enhance its reach and value. While many smaller biotechs concentrate exclusively on clinical trial results, Quoin’s dual strategy incorporates clinical trials with a focus on creating strong partnerships and the right commercial environment for its rare disease treatments.
Since its foundation in 2018, Quoin has worked to establish connections with foundations that support its patient population, as well as with physicians and leaders in the dermatology field who treat Netherton Syndrome, a rare and devastating genetic skin disease which currently has no treatment or cure. Quoin is positioned to deliver the first FDA-approved treatment for the disease with its lead candidate, QRX003 for Netherton Syndrome, and is targeting regulatory approvals for its pipeline of therapeutics in the United States and Europe in 2024, 2025 and 2026
These strategic relationships are already creating greater awareness about the need for rare disease treatment, addressing reimbursement issues and creating a receptive audience for the company’s therapeutic the moment it is broadly available.
Quoin is committed to developing solutions that improve the quality of life of rare disease patients and their families and has pledged to make its therapeutic available to every patient, everywhere, who is suffering from Netherton Syndrome. To advance the reach of its product ahead of regulatory approvals, Quoin has spent the past four months establishing exclusive distribution agreements with commercial partners in regions around the world. The company’s most recent partnership grants market leader, ER-Kim, exclusive rights to commercialize QRX003 in 15 countries across Central and Eastern Europe.
The company’s commercialization partnerships also include Latin America, the Middle East and North Africa, Russia and CIS (Commonwealth of Independent States) countries, Australia and New Zealand, covering 53 countries in total. Interestingly, a number of these countries have early access programs where therapeutics can be supplied ahead of formal regulatory approval on a named-patient basis. This can spark early revenue generation and real-world results, particularly as Quoin creates its own lean commercial sales and distribution structure for the US and Europe.
Quoin’s ability to leverage the value of partnerships stems from its management team’s extensive experience in successful product launch and commercialization and its dedication to supporting those who have been neglected by other pharmaceutical companies. With a balanced strategy and notable partnerships, Quoin has its sights set clearly on creating long-term value for shareholders while positively changing the lives of underserved patient populations.